THE INTERACTION OF RADIOTHERAPY AND CHEMOTHERAPY IN BREAST CANCER TREATMENT
Cytotoxic agents can increase the efficacy of radiation. Radiosensitizing effects (interaction within the radiation field) can be additive or supra-additive. Multiple mechanisms underlie radiosensitizing properties of cytotoxic agents and include increased radiation damage, inhibition of DNA repair,...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2008-04-01
|
| Series: | European Journal of Breast Health |
| Subjects: | |
| Online Access: |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/the-nteracton-of-radotherapy-and-chemotherapy-n-br/42624
|
| _version_ | 1828018648831229952 |
|---|---|
| author | Füsun Tokatlı |
| author_facet | Füsun Tokatlı |
| author_sort | Füsun Tokatlı |
| collection | DOAJ |
| description | Cytotoxic agents can increase the efficacy of radiation. Radiosensitizing effects (interaction within the radiation field) can be additive or supra-additive. Multiple mechanisms underlie radiosensitizing properties of cytotoxic agents and include increased radiation damage, inhibition of DNA repair, cell-cycle synchronization, increased cytotoxicity against hypoxic cells, inhibition of prosurvival pathways, and abrogation of rapid tumor cell repopulation. The agents, which have the most radiosensitizing effects, are cisplatin and paclitaxel. In addition to the classic cytotoxic agents with radiosensitizing properties several novel agents show promising interactions with radiation (e.g. EGFR inhibitors, antiangiogenic agents). Today, a sequential treatment is the standard treatment in the early stage breast cancer patients. However, concomitant chemotherapy and radiotherapy (RT) could be more appropriate to patients with high risk of recurrence, for example, in those with axillary lymph node metastases, close or positive surgical margins, large tumor size, young age and presence of lymphovascular invasion. Phase III trials are needed to define the benefits and the late effects of concomitant modern RT techniques (with 3 dimensional conformal, intensity modulated or image guided RT) with taxanes, capecitabine and targeted biologic agents in the adjuvant settings. |
| first_indexed | 2024-04-10T11:06:46Z |
| format | Article |
| id | doaj.art-a2a0c55d8dd54c90a32c0378bf50221a |
| institution | Directory Open Access Journal |
| issn | 2587-0831 |
| language | English |
| last_indexed | 2024-04-10T11:06:46Z |
| publishDate | 2008-04-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | European Journal of Breast Health |
| spelling | doaj.art-a2a0c55d8dd54c90a32c0378bf50221a2023-02-15T16:19:21ZengGalenos Publishing HouseEuropean Journal of Breast Health2587-08312008-04-0142707613049054THE INTERACTION OF RADIOTHERAPY AND CHEMOTHERAPY IN BREAST CANCER TREATMENTFüsun Tokatlı0 Trakya Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Edirne, Türkiye Cytotoxic agents can increase the efficacy of radiation. Radiosensitizing effects (interaction within the radiation field) can be additive or supra-additive. Multiple mechanisms underlie radiosensitizing properties of cytotoxic agents and include increased radiation damage, inhibition of DNA repair, cell-cycle synchronization, increased cytotoxicity against hypoxic cells, inhibition of prosurvival pathways, and abrogation of rapid tumor cell repopulation. The agents, which have the most radiosensitizing effects, are cisplatin and paclitaxel. In addition to the classic cytotoxic agents with radiosensitizing properties several novel agents show promising interactions with radiation (e.g. EGFR inhibitors, antiangiogenic agents). Today, a sequential treatment is the standard treatment in the early stage breast cancer patients. However, concomitant chemotherapy and radiotherapy (RT) could be more appropriate to patients with high risk of recurrence, for example, in those with axillary lymph node metastases, close or positive surgical margins, large tumor size, young age and presence of lymphovascular invasion. Phase III trials are needed to define the benefits and the late effects of concomitant modern RT techniques (with 3 dimensional conformal, intensity modulated or image guided RT) with taxanes, capecitabine and targeted biologic agents in the adjuvant settings. http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/the-nteracton-of-radotherapy-and-chemotherapy-n-br/42624 breast cancerconcomitant therapyradiosensitizing effectradiotherapychemotherapy |
| spellingShingle | Füsun Tokatlı THE INTERACTION OF RADIOTHERAPY AND CHEMOTHERAPY IN BREAST CANCER TREATMENT European Journal of Breast Health breast cancer concomitant therapy radiosensitizing effect radiotherapy chemotherapy |
| title | THE INTERACTION OF RADIOTHERAPY AND CHEMOTHERAPY IN BREAST CANCER TREATMENT |
| title_full | THE INTERACTION OF RADIOTHERAPY AND CHEMOTHERAPY IN BREAST CANCER TREATMENT |
| title_fullStr | THE INTERACTION OF RADIOTHERAPY AND CHEMOTHERAPY IN BREAST CANCER TREATMENT |
| title_full_unstemmed | THE INTERACTION OF RADIOTHERAPY AND CHEMOTHERAPY IN BREAST CANCER TREATMENT |
| title_short | THE INTERACTION OF RADIOTHERAPY AND CHEMOTHERAPY IN BREAST CANCER TREATMENT |
| title_sort | interaction of radiotherapy and chemotherapy in breast cancer treatment |
| topic | breast cancer concomitant therapy radiosensitizing effect radiotherapy chemotherapy |
| url |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/the-nteracton-of-radotherapy-and-chemotherapy-n-br/42624
|
| work_keys_str_mv | AT fusuntokatlı theinteractionofradiotherapyandchemotherapyinbreastcancertreatment AT fusuntokatlı interactionofradiotherapyandchemotherapyinbreastcancertreatment |